Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aptahem ABXSAT:APTA -0.35%30 EV-to-EBITDA is -1.89 as of Aug. 17, 2026. GuruFocus rates XSAT:APTA with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 401 Biotechnology companies, Aptahem AB ranks worse than 249376.31% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aptahem AB's enterprise value is kr10.65 Mil.
Aptahem AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr-5.64 Mil. Therefore, Aptahem AB's EV-to-EBITDA for today is -1.89.
The historical rank and industry rank for Aptahem AB's EV-to-EBITDA or its related term are showing as below:
XSAT:APTA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.14 Med: -0.21 Max: 0.99
Current: -1.89
During the past 12 years, the highest EV-to-EBITDA of Aptahem AB was 0.99. The lowest was -9.14. And the median was -0.21.
XSAT:APTA's EV-to-EBITDA is ranked worse than 100% of 401
companies
in the Biotechnology industry
Industry Median: 13.8
vs XSAT:APTA: -1.89
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aptahem AB's share price for today is kr0.57.
Aptahem AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.301.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Aptahem AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:APTA vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Aptahem AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptahem AB EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aptahem AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aptahem AB's EV-to-EBITDA falls into.
Aptahem AB's current Enterprise Value is kr10.65 Mil.
Aptahem AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-5.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aptahem AB (XSAT:APTA) has a EV-to-EBITDA of -1.89 as of Aug. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aptahem AB. According to the industry distribution chart, Aptahem AB ranks #999999 out of 401 companies in the Biotechnology industry.
Is Aptahem AB's EV-to-EBITDA too high?
Aptahem AB's current EV-to-EBITDA is -1.89. Based on the distribution chart, Aptahem AB ranks #999999 out of 401 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aptahem AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Aptahem AB's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Aptahem AB ranks #999999 out of 401 companies for EV-to-EBITDA. This places Aptahem AB in the lower half of its industry. The industry median EV-to-EBITDA is 13.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.80, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aptahem AB. For the Biotechnology industry, the median EV-to-EBITDA is 13.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aptahem AB's current EV-to-EBITDA is -1.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptahem AB stock overvalued right now?
Aptahem AB (XSAT:APTA) has a current EV-to-EBITDA of -1.89. The current EV-to-EBITDA is -1.89. Aptahem AB's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Aptahem AB (XSAT:APTA), the current EV-to-EBITDA is -1.89 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aptahem AB develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's main candidate Apta-1 is developed as an emergency medicine intended to prevent the occurrence of life-threatening organ and tissue damage in patients suffering from sepsis.
30GF Score
Get the complete analysis for XSAT:APTA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:APTA has been successfully added to your 
